Drug Trial Radar · NCT01800825
Clindamycin to Reduce Preterm Birth in a Low Resource Setting
Last checked: Nov 19, 2026Latest source record: Jul 18, 2016 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
1,726
Actual
Start
Jul 2013
Primary completion
Apr 2016
Study completion Apr 2016
Sponsor
- Lead sponsor
- Christiana Care Health ServicesAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- Collaborators
- Jawaharlal Nehru Medical College; Thrasher Research Fund
- First posted
- Feb 28, 2013
Design
- Study type
- Interventional
- Phase
- Phase 4
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Prevention
- Who can join
- Female only, from 13 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
Preterm birth has been linked to certain types of vaginal infections. The goal of this study is to determine if giving women pregnant between 13-20 weeks with an elavated vaginal pH(evidence of this type of infection)Oral Clindamycin(an antibiotic)will have a lower rate of preterm birth compared to women given a placebo(starch)
Conditions
- Pregnancy
- Prematurity
- Preterm Birth
- Bacterial Vaginosis
Interventions
ClindamycinDrug
Clindamycin 300 mg Orally will be administered twice daily for a total of 5 days
PlaceboDrug
This will be an identical placebo comparator made of starch.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Preterm birth prior to 37 weeksTime frame: Time of birth
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Jawaharlal Nehru Medical College
Belagavi, Karnataka, India
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.